Bausch Health posts strong Q3 2026 results and lifts full‑year outlook
Bausch Health reported third‑quarter 2026 revenue of $2.94 billion, up 10% year‑over‑year, and adjusted earnings per share of $1.77, a 53% increase. The company raised its full‑year 2026 revenue guidance to $10.975 billion‑$11.175 billion and adjusted EBITDA guidance to $4.315 billion‑$4.415 billion. It also authorized a $50 million share repurchase program and reduced net debt by more than $500 million during the quarter.
Why it matters
The higher guidance suggests stronger earnings and cash flow potential for the rest of 2026, which may support the stock price and attract income‑focused investors. The share buyback and debt reduction improve balance‑sheet flexibility and could enhance shareholder returns.
Key facts
- 1Consolidated reported revenue for Q3 2026 was $2.94 billion, a 10% increase over the prior year period. stocktitan.net
- 2Adjusted earnings per diluted share rose to $1.77, up from $1.16 a year earlier. investing.com
- 3Full‑year 2026 consolidated revenue guidance was raised to $10.975 billion‑$11.175 billion. investing.com
- 4Full‑year 2026 adjusted EBITDA guidance was raised to $4.315 billion‑$4.415 billion. investing.com
- 5The board authorized a $50 million share repurchase programme. investing.com
- 6Net debt was reduced by more than $500 million during the quarter. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.